TB500 5mg

TB500 5mg is a synthetic peptide analogue of thymosin beta-4 (Tβ4), a naturally occurring actin-sequestering protein involved in cell migration, angiogenesis, and tissue repair. This formulation is designed for research and laboratory use, providing a precise quantity of lyophilised peptide for controlled experimental protocols. TB500 has been investigated in preclinical models for its role in promoting cellular migration, wound healing, and vascular repair. Each vial is manufactured to research-grade purity standards to ensure consistency and reliability in experimental settings. Ideal for qualified researchers and institutions studying thymosin beta-4 biology, regenerative pathways, and actin dynamics. Store in a cool, dry place away from direct light. For research purposes only. Not intended for human or veterinary use.

Specifications: Active Ingredient: TB500 (Thymosin Beta-4 synthetic analogue) Concentration: 5mg per vial Purity: ≥98% (HPLC) Form: Lyophilised powder Appearance: White to off-white lyophilised powder Molecular Formula: C₂₁₂H₃₅₀N₅₆O₇₈S Molecular Weight: 4963.4 Da CAS Number: 77591-33-4 Mechanism: Actin sequestration, promotion of cellular migration, angiogenesis, and anti-apoptotic signalling via integrin-linked kinase (ILK) activation Storage: 2–8°C (refrigerated) Shelf Life: 2–3 years when stored properly in sealed conditions Reconstitution: Bacteriostatic water or sterile saline Intended Use: Laboratory and research applications only

Storage Before Reconstitution: Store in original sealed vial at 2–8°C away from direct sunlight and moisture. Stable for 2–3 years when stored properly. Storage After Reconstitution: Store reconstituted solution at 2–8°C and use within 2–4 weeks. For extended storage, freeze at −20°C in aliquots. Avoid repeated freeze-thaw cycles. Use sterile technique throughout reconstitution. For research use only. Not intended for human or veterinary use.

Research References

The following peer-reviewed studies and publications are provided for informational and scientific reference purposes only. They do not constitute medical claims or endorsements of this product for any therapeutic use.

1. Thymosin Beta-4: Actin Sequestration and Tissue Repair
   Goldstein AL, Hannappel E & Kleinman HK. (2005). Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine, 11(9), 421–429. https://doi.org/10.1016/j.molmed.2005.07.004
   Establishes thymosin beta-4’s dual role as an actin-sequestering protein and a pleiotropic tissue repair mediator, covering its promotion of cell migration, angiogenesis, and anti-apoptotic signalling — the foundational mechanistic reference for all TB500 research.
2. TB500 and Integrin-Linked Kinase Activation in Cardiac Repair
   Bock-Marquette I, et al. (2004). Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature, 432(7016), 466–472. https://doi.org/10.1038/nature03000
   Landmark study demonstrating that thymosin beta-4 activates integrin-linked kinase (ILK), promoting cardiomyocyte survival, migration, and cardiac repair following ischaemic injury in mouse models — establishing the ILK signalling axis as a key research target for TB500 cardioprotection studies.
3. Thymosin Beta-4 and Wound Healing in Preclinical Models
   Philp D, et al. (2003). Thymosin beta 4 and a synthetic tetrapeptide AcSDKP promote dermal and epidermal healing in db/db diabetic mice. Wound Repair and Regeneration, 11(1), 19–24. https://doi.org/10.1046/j.1524-475X.2003.11104.x
   Demonstrates accelerated dermal and epidermal wound healing following thymosin beta-4 administration in diabetic mouse models, providing quantitative wound closure data and establishing its role in keratinocyte and fibroblast migration relevant to tissue repair research.
4. Thymosin Beta-4 and Angiogenesis
   Grant DS, et al. (1999). Thymosin beta4 enhances endothelial cell differentiation and angiogenesis. Angiogenesis, 3(2), 125–135. https://doi.org/10.1023/A:1009041911493
   Demonstrates that thymosin beta-4 promotes endothelial cell differentiation, tube formation, and angiogenesis in vitro and in vivo, establishing its pro-angiogenic activity and providing mechanistic context for TB500 research in vascular repair and neovascularisation models.
5. Thymosin Beta-4 and Tendon Repair
   Bock-Marquette I, et al. (2009). Thymosin beta-4 mediated PKC activation is essential to initiate the embryonic coronary developmental program and epicardial progenitor cell activation in adult mice in vivo. Journal of Molecular and Cellular Cardiology, 46(5), 728–738. (See also: Guarnera G, et al. (2010). Thymosin beta-4 activates integrin-linked kinase and promotes tendon repair. Annals of the New York Academy of Sciences, 1194, 204–210.) https://doi.org/10.1111/j.1749-6632.2010.05490.x
   Demonstrates thymosin beta-4’s role in tendon repair via ILK activation, promoting tenocyte migration and collagen synthesis in preclinical models — providing relevant context for researchers investigating TB500 in musculoskeletal tissue repair protocols.

All references are cited for scientific context only. This product is supplied strictly for in vitro laboratory research. It is not approved for human or veterinary use.